Structured population data were available for 8 of 8 supporting studies. 7 studies described participants with type 2 diabetes. 8 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

4 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Dapagliflozin 10 mg

Core clinician-reference fields are available or not applicable.

Patients received a fixed-dose combination of dapagliflozin and gliclazide for 16 weeks.

FDC of Dapagliflozin 10 mg + Gliclazide SR 60 mg

Patients in the test arm received FDC of dapagliflozin 10 mg and gliclazide 60 mg SR tablets, while those in the reference arm received dapagliflozin 10 mg, given orally every day for 16 weeks of the treatment period.

Patients received dapagliflozin 10 mg monotherapy for 16 weeks.

Patients in the reference arm received dapagliflozin 10 mg, given orally every day for 16 weeks of the treatment period.

Authoritative quality diagnostic: invalid or missing unit.

Dapagliflozin and Gliclazide Combination Improves Glycemic Control

Not extracted from the authoritative source.

Not applicable to this study design or comparison.

Available source content was suppressed because validation identified a conflict.

Clinician-reference record is usable with limitations in: arms, risk_of_bias.

Authoritative quality diagnostic: rob tool design incompatible.

Dapagliflozin may improve RAAS markers in diabetes patients

Not reported in the authoritative source.

Clinician-reference record is usable with limitations in: design, risk_of_bias.

Patients with newly diagnosed T2DM treated with Dapagliflozin for 3 months.

Dapagliflozin Treatment

All patients were treated with Dapagliflozin 10 mg/day, primary and secondary endpoints were assessed by cardiorenal markers (albumin-to creatinine ratio (ACR) and calculated glomerular filtration rate (GFR)), metabolic marker (HbA1c), Anthropometric parameters (BMI and blood pressure), were measured at baseline and follow-up.

Authoritative quality diagnostic: authoritative design unavailable.

Authoritative quality diagnostic: sample size arm total mismatch.

Dapagliflozin improves kidney function in early T2DM

Vit E group

Patients receiving dapagliflozin for 24 weeks.

Dapa group

The Dapa group received 5 mg/day of dapagliflozin post-breakfast (with an optional increase to 10 mg, as determined by the attending physician), while the Vit E group received 150 mg/day of tocopherol acetate (50 mg three times daily post-meal). Both groups continued the daily medication for 24 weeks.

Patients receiving vitamin E for 24 weeks.

Dapagliflozin improves metabolic outcomes in type 2 diabetes patients

Clinician-reference record is usable with limitations in: design, arms, risk_of_bias.

Dapagliflozin-linagliptin combo improves glycemic control and organ protection

Loose combination (LC) arm

Participants received one tablet containing dapagliflozin 10 mg and pioglitazone 15 mg, administered orally once daily in the morning.

Fixed-dose combination (FDC) arm

Participants were randomized in a 1:1 ratio to receive one of the two study treatments for 12 weeks, in addition to their background metformin regimen. FDC arm One tablet containing dapagliflozin 10 mg and pioglitazone 15 mg, administered orally once daily in the morning.

Participants received the same agents administered separately as an add-on therapy to stable metformin.

Participants were randomized in a 1:1 ratio to receive one of the two study treatments for 12 weeks, in addition to their background metformin regimen. LC arm: same agents administered separately.

Dapagliflozin-pioglitazone combo improves glycemic control in type 2 diabetes

Dapagliflozin

Patients received PEG-Loxe administered subcutaneously once weekly, starting with an initial dose of 0.1 mg for 4 weeks, followed by a maintenance dose of 0.2 mg.

PEG-Loxe

PEG-Loxe was administered subcutaneously once weekly. The treatment adhered to a fixed-dose escalation schedule, starting with an initial dose of 0.1 mg for 4 weeks, followed by a maintenance dose of 0.2 mg until study completion.

Patients received dapagliflozin initiated at 5 mg for 2 weeks, followed by a maintenance dose of 10 mg until the study's conclusion.

Dapagliflozin was initiated at 5 mg for 2 weeks, followed by a maintenance dose of 10 mg until the study's conclusion.

PEG-Loxe improves urine protein levels in diabetic kidney disease

Dapagliflozin group

Patients received pioglitazone (25 mg/15 mg) once daily, along with metformin twice daily.

Pioglitazone group

The pioglitazone group received a fixed dose combination tablet (alogliptin/pioglitazone [25 mg/15 mg]) once daily, along with metformin twice daily.

Patients received dapagliflozin (10 mg) once daily, an alogliptin tablet (25 mg) once daily, and metformin tablets twice daily.

The dapagliflozin group received a dapagliflozin tablet (10 mg) once daily, an alogliptin tablet (25 mg) once daily, and metformin tablets (≥500 mg) twice daily for 26 weeks.

Authoritative quality diagnostic: invalid or missing value.

Dapagliflozin × HbA1c

Available supporting studies